(Q24201821)

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Treatment of branch retinal vein occlusion induced macular edema with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Retinal vein occlusion and the prevalence of lipoprotein abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Retinal vein occlusion: beyond the acute event

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Results of bevacizumab as the primary treatment for retinal vein occlusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Prognostic factors for retinal vein occlusion: prospective study of 175 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Ranibizumab for the treatment of neovascular age-related macular degeneration: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Interventions for branch retinal vein occlusion: an evidence-based systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Early Avastin management in acute retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Natural history of branch retinal vein occlusion: an evidence-based systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

New vessel formation in retinal branch vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Bevacizumab in retinal vein occlusion-results of a prospective case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Retinal vein occlusions and mortality: the Beijing Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

Histopathologic study of nine branch retinal vein occlusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

7 January 2021

Hypoxic regulation of vascular endothelial growth factor in retinal cells

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

7 January 2021

Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

7 January 2021

[Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

7 January 2021

Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

7 January 2021

Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

7 January 2021

Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

7 January 2021

Diabetes mellitus and retinal vein occlusion in patients of Asian, west Indian and white European origin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

7 January 2021

Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009510.PUB2

7 January 2021